New Oral Drug Zuranolone (Zurzuvae) for Postpartum Depression is Now Available
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
Can We use the Electronic Health Record to Predict Risk for Postpartum Depression?
Machine learning can be used to analyze data contained within the electronic health record to accurately predict which individuals are at increased risk for postpartum depression.
Prediction of Postpartum Depression: Take a Closer Look at Question 3 on the PHQ-9
A routinely administered single-item measure of sleep disturbance could identify pregnant individuals who are at risk for PPD and may benefit from depression prevention efforts.
Using Metabolic Biomarkers to Predict Risk for Postpartum Depression
Metabolic biomarkers in the cerebrospinal fluid may be used to identify women at high risk for postpartum depression.
New Oral PPD Treatment Zuranolone Will Soon Hit the Market as Zurzuvae
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
Update on Postpartum Depression Documentary: More Than Blue
We are looking to include two additional women who are early on in the postpartum period (under one year) and recovering from postpartum depression.
ADHD as a Risk Factor for Postpartum Depression and Anxiety
ADHD is an important risk factor for both depression and anxiety disorders in the postpartum period and should be considered in the post-pregnancy maternal care.
Planned Initiatives from the Department of Health and Human Services Focus on Maternal Mental Health
 Some good news from our colleagues at the Maternal Mental Health Leadership Alliance (MMHLA)... The United States Department of Health and Human Services (HHS) is planning to launch significant initiatives addressing the maternal mental [...]
Zuranolone: A novel postpartum depression treatment, with lingering questions
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on zuranolone for postpartum depression with Ob.Gyn News on August 15, 2023.
A New Study Investigates the Impact of a Drospirenone-Only Contraceptive Pill On Postpartum Mood
Postpartum women taking a drospirenone-only contraceptive pill experienced a decrease in depressive symptoms.